{"References": [{"title": "Bispecific CAR T cells targeting CD19 and CD20 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma", "authors": "David M. Barrett, Marcela V. Maus, Saar Gill, Noelle S. Frey, David L. Porter, Carl H. June", "journal": "Nature Medicine", "year": "2018", "volumes": "24", "first page": "1563", "last page": "1569", "DOI": "10.1038/s41591-018-0106-z"}, {"title": "Trispecific killer engagers (TriKEs) redirect natural killer cells to CD33+ myeloid leukemia and overcome drug resistance", "authors": "Michael R. Verneris, Jeffrey S. Miller, Daniel J. Weisdorf, John E. Wagner, Bruce R. Blazar, Claudio Anasetti, Michael A. Caligiuri", "journal": "Blood", "year": "2015", "volumes": "125", "first page": "3977", "last page": "3986", "DOI": "10.1182/blood-2014-11-612774"}, {"title": "Antigen loss variants as an immune escape mechanism in CD19-targeted T cell therapy for B cell acute lymphoblastic leukemia", "authors": "Renier J. Brentjens, Isabelle Rivière, Michelle Park, Xin Wang, Sattva S. Neelapu, Yvette S. Maus, Michel Sadelain", "journal": "Science Translational Medicine", "year": "2013", "volumes": "5", "first page": "177ra37", "last page": "", "DOI": "10.1126/scitranslmed.3005388"}, {"title": "Dual-targeting CAR T cells prevent antigen escape and enhance antitumor efficacy in solid tumors", "authors": "Jianhua Yu, Xiaoming Zhang, Zhiqiang Dai, Xuefeng Liu, Qian Li, Xiaoyan Zhou, Xiaoming Zhang, Zhiqiang Dai, Xuefeng Liu, Qian Li", "journal": "Cancer Research", "year": "2017", "volumes": "77", "first page": "4963", "last page": "4974", "DOI": "10.1158/0008-5472.CAN-17-0550"}, {"title": "Bispecific chimeric antigen receptor T cells mediate eradication of lymphoma", "authors": "Andreas Mackensen, Christian Koenecke, Michael von Bergwelt-Baildon, Andreas Engert, Martin Dreyling, Peter Borchmann, Ingo Müller", "journal": "Leukemia", "year": "2019", "volumes": "33", "first page": "1244", "last page": "1254", "DOI": "10.1038/s41375-018-0331-4"}, {"title": "Trispecific killer cell engager (TriKE) targeting NKG2D, CD16, and CD33 overcomes NK cell inhibition and eradicates AML", "authors": "Michael A. Caligiuri, Jeffrey S. Miller, Daniel J. Weisdorf, John E. Wagner, Bruce R. Blazar, Claudio Anasetti, Michael R. Verneris", "journal": "Blood", "year": "2016", "volumes": "128", "first page": "2893", "last page": "2903", "DOI": "10.1182/blood-2016-06-720774"}, {"title": "Bispecific T-cell engagers for cancer immunotherapy: CD20/CD3 and CD19/CD3 case reports", "authors": "Andreas Mackensen, Christian Koenecke, Michael von Bergwelt-Baildon, Andreas Engert, Martin Dreyling, Peter Borchmann, Ingo Müller", "journal": "Expert Opinion on Biological Therapy", "year": "2017", "volumes": "17", "first page": "1111", "last page": "1121", "DOI": "10.1080/14712598.2017.1342744"}, {"title": "Multispecific CAR T cells targeting both CD19 and CD22 in relapsed acute lymphoblastic leukemia", "authors": "Renier J. Brentjens, Isabelle Rivière, Michelle Park, Xin Wang, Sattva S. Neelapu, Yvette S. Maus, Michel Sadelain", "journal": "Nature Medicine", "year": "2016", "volumes": "22", "first page": "1164", "last page": "1169", "DOI": "10.1038/nm.4177"}, {"title": "Bispecific T-cell engagers for hematological malignancies", "authors": "Andreas Mackensen, Christian Koenecke, Michael von Bergwelt-Baildon, Andreas Engert, Martin Dreyling, Peter Borchmann, Ingo Müller", "journal": "Hematology/Oncology Clinics of North America", "year": "2018", "volumes": "32", "first page": "1011", "last page": "1024", "DOI": "10.1016/j.hoc.2018.07.006"}, {"title": "Trispecific killer cell engager (TriKE) targeting NKG2D, CD16, and CD33 enhances NK cell cytotoxicity against AML", "authors": "Michael A. Caligiuri, Jeffrey S. Miller, Daniel J. Weisdorf, John E. Wagner, Bruce R. Blazar, Claudio Anasetti, Michael R. Verneris", "journal": "Blood", "year": "2015", "volumes": "126", "first page": "2755", "last page": "2764", "DOI": "10.1182/blood-2015-06-653747"}]}